益气解毒化瘀方联合抗病毒治疗对难治性慢性丙型肝炎患者外周血淋巴细胞亚群和炎性细胞因子的影响

doi:10.3969/j.issn.1672-5069.2016.06.009

摘要/Abstract

摘要： 目的探讨益气解毒化瘀方联合抗病毒治疗对难治性慢性丙型肝炎（DT-CHC）患者外周血淋巴细胞亚群及炎性因子的影响。方法选择2013年3 月～2015年2 月收治的84例难治性慢性丙型肝炎患者为研究对象，采用随机数字表法随机分为观察组和对照组（各42 例）。给予对照组聚乙二醇干扰素（Peg-INF-α）联合利巴韦林治疗，观察组采用益气解毒化瘀方联合Peg-INF-α和RBV治疗。随访6 个月，比较两组临床疗效、淋巴细胞亚群、炎性因子变化。结果治疗6个月时，观察组总有效率和HCV RNA转阴率分别为81.0%和14.3%，均显著高于对照组（57.1%和2.4%，P<0.05）；观察组外周血CD3+、CD4+、CD4/CD8和CD8+细胞分别为（69.3±6.1）%、（36.4±4.2）%、（1.4±0.4）和（25.4±2.5）%，显著高于对照组【分别为（62.5±5.5）%、（30.2±3.6）%、（1.1±0.4）和（26.9±3.5）%，P<0.05】；观察组L-选择素、可溶性细胞间粘附分子、白细胞介素-6、肿瘤坏死因子-α含量分别为（886.2±154.5） ng/ml、（258.7±65.4） ng/ml、（88.7±11.6） pg/ml和（1.3±0.5） ng/m，均显著低于对照组【分别为（1268.9±235.8） ng/ml、（379.6±80.3） ng/ml、（121.6±14.2） pg/ml和（1.6±0.5） ng/ml，P<0.05】；观察组治疗后白细胞和血小板计数均明显高于对照组（P<0.05）。结论益气解毒化瘀方联合Peg-INF-α和利巴韦林治疗能有助于缓解难治性丙型肝炎患者病毒学应答率，改善免疫功能，减少对骨髓抑制的影响，提高治疗效果。

关键词: 慢性丙型肝炎, 益气解毒化瘀方, α-干扰素, 淋巴细胞亚群, 炎性因子

Abstract: Objective To explore the effect of Yiqi Jiedu Huayu compound combined with antiviral therapy on peripheral blood lymphocyte subsets and inflammatory cytokines in patients with refractory chronic hepatitis C （CHC）. Methods 84 patients with refractory CHC between March 2013 and February 2015 were recruited in this study and they were randomly divided into observation group and control group with 42 cases in each. Patients in control group were given polyethylene glycol interferon combined with ribavirin as antiviral therapy，while patients in observation group received Yiqi Jiedu Huayu compound at the base of antiviral therapy. All patients were followed up for 6 months，and clinical efficacy，peripheral blood lymphocyte subsets，inflammatory cytokines were observed and compared between the two groups. Results At the end of 6-month treatment，the total effective rates and negative conversion rates of HCV RNA in observation group were 81.0% and 14.3%，significantly higher than those in control group（57.1% and 2.4%，respectively，P<0.05 for both）；Patients in observation group had higher percentage of CD3+cells，CD4+cells and the ratio of CD4/CD8，but lower percentage of CD8+ cells than patients in control group [（69.3±6.1）% vs.（62.5±5.5）%，（36.4±4.2）% vs. （30.2±3.6）%，（1.4±0.4） vs. （1.1±0.4） and （25.4±2.5）% vs. （26.9±3.5）%，respectively，P<0.05 for all]；Serum levels of L-selectin，soluble intercellular adhesion molecule，interlukin-6 and TNF-α in observation group were lower than those in control group [（886.2±154.5） ng/ml vs. （1268.9±235.8） ng/ml，（258.7±65.4） ng/ml vs. （379.6±80.3） ng/ml，（88.7±11.6） pg/ml vs. （121.6±14.2） pg/ml，（1.3±0.5） ng/ml vs. （1.6±0.5） ng/ml，respectively，P<0.05 for all]；The patients in observation group had higher white blood cell and platelet counts than in control group（P<0.05）. Conclusion Yiqi Jiedu Huayu compound combined with antiviral therapy is able to attenuate the inflammatory reactions，modulate lymphocyte subset disorders，reduce bone marrow suppression，and improve the clinical efficacy in patients with refractory CHC.

Key words: Chronic hepatitis C, Yiqi Jiedu Huayu compound, Interferon-α, Lymphocyte subsets, Inflammatory cytokines

冯晓霞，聂苑霞，梁海林. 益气解毒化瘀方联合抗病毒治疗对难治性慢性丙型肝炎患者外周血淋巴细胞亚群和炎性细胞因子的影响[J]. 实用肝脏病杂志, 2016, 19(6): 674-677.

Feng Xiaoxia，Nie Yuanxia，Liang Hailin.. Impact of Yiqi Jiedu Huayu compound combined with antiviral therapy on peripheral blood lymphocyte subsets and inflammatory cytokines in patients with refractory chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 674-677.

参考文献

[1] 中华医学会肝病学分会，中华医学会感染病学会分会.丙型肝炎防治指南. 实用肝脏病杂志，2016，19（4）:Ⅸ-ⅩⅩⅥ.
[2] Patsenker E，Sachse P，Chicca A，et al.Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. Int Mol Sci，2015，16（4）:7057-7056.
[3] 廖柏明，罗光汉，朱海鹏.不同剂量聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的效果及安全性观察.中国医药导报，2013，10（24）:92-94.
[4] 于晓雯，薛博瑜. 难治性丙型肝炎中西医治疗研究. 长春中医药大学学报，2013，29（1）:97-99.
[5] 游宏声，金生. 2011年欧洲肝病研究学会丙型肝炎防治指南推荐意见介绍. 实用肝脏病杂志，2011，14（4）:307-308，320.
[6] 上海市中医药学会肝病分会专业委员会，国家“十一五”科技重大专项重大传染病中医药防治课题组.中国慢性丙型肝炎中医辨证分型规范研究. 上海中医药杂志，2012，46（3）:11-12.
[7] 郑彼萸. 中药新药临床研究指导原则. 北京:中国医药科技出版社，2002:115-119.
[8] Hwang Y，Kim W，Kwon SY，et al.Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.Korean J Intern Med，2015，30（6）:792-800.
[9] 陈斗仁，刘兴丽，刘小艳，等. 干扰素α-2a 联合利巴韦林抗丙型肝炎病毒感染的临床研究. 中华医院感染学杂志，2015，18:4163-4165.
[10] 张琼，胡蓉，毛创杰，等. 难治性丙型肝炎临床病理特点及中配药抗病毒治疗效果比较. 疑难病杂志，2015，14（3）:251-253.[11] 沈健，陈建杰，商斌仪，等. 丙肝冲剂治疗难治性丙型肝炎研究.现代中西医结合杂志，2013，22（18）:1947-1949.
[12] 赵琳，陈建杰，聂红明，等. 芪术冲剂加减治疗难治性病毒性丙型肝炎的临床研究. 中西医结合肝病杂志，2014，24（4）:197-199.
[13] Barathan M，Gopal K，Mohamed R，et al. Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Apotosis，2015，20（4）:466-480.
[14] Chalupa P，Holub M，Davidová A，et al. Immune response in the pathogenesis of hepatitis C virus infection.Epidemiol Mikrobiol Imunol，2015，64（4）:198-203.
[15] Zhang L，Hao CQ，Miao L，et a. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy. Genet Mol Res，2014，13（4）:9747-9755.
[16] Flynn JK，Dore GJ，Hellard M，et al. Maintenance of Th1 hepatitis C virus （HCV）-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment. J Gastroenterol Hepatol，2013，28（11）:1770-1781.
[17] MacParland SA，Chen AY，Corkum CP，et al. Patient-derived hepatitis C virus inhibits CD4 but not CD8 T lymphocyte proliferation in primary T cells.Virol J，2015，19（12）:93.